Patent · US Active

Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

US11254681B2 · kind B2 · utility

1Cited by
6References
54Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 11, 2020
Grant dateFeb 22, 2022
Priority date—
Expiry dateMay 11, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D471/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.